



Corporate Summary

AIM: EVG.L
NOMAD: Cavendish
IR: Instinctif, CAG



THIS PRESENTATION (AS DEFINED BELOW) IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA, AUSTRALIA, JAPAN, NEW ZEALAND AND THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

This document and the related verbal presentation (together the "Presentation") are for your information only, and are being delivered by Evgen Pharma plc (the "Company" or "Evgen") which trades on the AIM market of the London Stock Exchange under ticker EVG.

By attending this Presentation, you agree to be bound by the following conditions. Please note that the information in this Presentation has yet to be announced or otherwise made public and some or all of the information in this Presentation or any discussion surrounding the Presentation may constitute inside information relating to the securities of the Company within the meaning of the insider dealing provisions of the Criminal Justice Act 1993 and/or of the EU Market Abuse Regulation (Regulation 596/2014) as it applies in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). By accepting this Presentation the recipient agrees to comply with its obligations under the MAR, including by not making use of any of inside information for the purpose of dealing, or of counselling or procuring any other person to deal, in the securities of the Company. The information and opinions contained in this Presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this Presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this and any errors therein or omissions therefrom.

This document is not an admission document or a prospectus. This document does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefor. This Presentation has not been authorised or approved for the purposes of section 21 of the Financial Services and Markets Act 2000 and therefore it is being delivered for information purposes within (a) the United Kingdom only to persons (i) who have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or are high net worth entities falling within Article 49(2)(a) to (d) of the Order and investment personnel of any of the foregoing (each within the meaning of the Order); and (ii) who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) as it applies in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 ("Qualified Investors"); and (iii) to whom the Presentation may otherwise lawfully be communicated; (b) the European Economic Area (the "EEA") only to Qualified Investors (all such persons together being referred to as "Relevant Persons" and each a "Relevant Person"). By accepting this Presentation and not immediately returning it, the recipient represents and warrants that they are a Relevant Person and agrees to be bound by the following conditions. This Presentation is not to be disclosed to any other person or used for any other purpose.

If you are in any doubt about the contents of this document, you should consult a person authorised under the Financial Services and Markets Act 2000 who specialises in advising on the acquisition of shares and securities of unlisted companies. You should be aware that an investment in the Company involves a high degree of risk and investors should be aware of such risks and should rely on their own examination of the Company and make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser. Any investment or investment activity to which this document relates is only available to Relevant Persons. Persons of any other description should not rely on this document or act on its contents for any purpose whatsoever and should return it to the Company immediately.

The distribution of this Presentation in certain jurisdictions may be restricted by law, and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions. Although reasonable care has been taken to ensure that the facts stated in this Presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this Presentation have not been verified by the Company or any other person. Accordingly no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this Presentation and no reliance should be placed on such information or opinions. None of the Company, or any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this Presentation. No part of this Presentation, or the fact of its distribution, should form the basis of or be relied upon in connection with any contract or commitment or investment decision whatsoever.

Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with the Company or its representatives as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the Company or any transaction to be entered into by any member of the Evgen group. No undertaking, representation or warranty, express or implied, is given by the Company, any member of the Evgen group, or any of their respective current or proposed directors, officers, partners, employees, secondees, agents or advisers or any other person as to the accuracy or completeness of the information or as to the opinions contained in this document and no liability is accepted for any such information or opinions. Further, the information in this Presentation is not complete and may be changed. Recipients of this Presentation should each make their own independent evaluation of the information and of the relevance and adequacy of the information in this document and should make such other investigations as they deem necessary.


This Presentation may contain forward-looking statements that reflect the Company's current views and expectations regarding future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "envisages", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "could", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward looking statements. These forward-looking statements include matters that are not historical facts and speak only as of the date of this Presentation. They appear in a number of places throughout this document and include statements regarding the Company and the directors, and the directors' current intentions, beliefs or expectations concerning, amongst other things, to management's strategic vision, aims and objectives, the conduct of clinical trials, the filing dates for product licence applications and the anticipated launch of specified products in various markets, the Company's ability to find partners for the development and commercialisation of its products as well as the terms for such partnerships, anticipated levels of demand for existing products and products in development, the effect of competition, anticipated efficiencies, trends in results of operations, margins, the overall pharmaceutical market and exchange rates, are all forward looking in nature.

Evgen - A Clinical Stage Drug Development Company

Focus on brain, breast and other cancers

SFX-01 has three molecular targets, STAT 3, Nrf2 and SHP2

- Developing a new class of pharmaceuticals - based on highly biologically active “sulforaphane” - applications in multiple therapeutic areas based on a network of targets
- Strong third party pre-clinical and clinical data on sulforaphane
- Unique platform technology – Sulforadex[®], stabilises unstable sulforaphane, lead SFX-01
- Strong, granted IP covering composition, manufacturing and novel derivatives
- Highly experienced board and management
- Business model: establish proof of concept and partner. Multiple value inflection points
- Out-license partnership with STALICLA SA (SFX-01 for neurodevelopmental disorders and schizophrenia)





EVGEN
pharma


Conserve Cash

External
Validation of
Technology


Biotech
Imperatives
2023

Generate Pre-
clinical Data

Generate
Clinical
Data



Our Pipeline



SFX-01 in HR+ HER 2- Breast Cancer


- Breast cancer - genetically and clinically heterogeneous disease with multiple subtypes. HR+ HER2- subtype is the most common of all the breast cancer subtypes.
- The total market size in the 8MM for HER2- breast cancer is estimated to expand to **\$12.22 billion** by 2028
- In 2018, HER2-/HR+ represented 67.32% cases of diagnosed incident cases of invasive breast cancer in the 8MM
- Cases are highest in the United States accounting for **~201,400** cases in 2020 with most cases occurring in people aged between 60 to 79 years
- Typical treatment involves, hormone therapy to block estrogen effects on cancer cells, surgery, such as lumpectomy or mastectomy, radiation therapy to target any remaining cancer cells. In more advanced cases, chemotherapy or targeted therapies like CDK4/6 inhibitors are considered.
- The treatment of patients who experience disease progression on CDK4/6 inhibitors and endocrine therapy remains challenging

Clinically:

- SFX-01 is well tolerated in combination with endocrine therapy
- SFX-01 shows anti-tumour activity in tumours that have progressed on endocrine therapy


CDK4/6 inhibitor resistant disease:

- SFX-01 shows anti-tumour activity in preclinical models of CDK4/6 inhibitor resistance



SFX-01 in Glioblastoma

- **Very poor life expectancy**, average time to death after diagnosis 14 months, 5% five-year survival. Current treatments: surgical resection, radiotherapy and chemotherapy, frequent relapses
- Epidemiologists forecast an increase in the diagnosed incident cases of brain cancer in the 8MM, from **121,646** in 2020 to **147,148** in 2030
- Sales of glioblastoma therapies estimated at **\$549.1m in 2020** across the 8MM. Market is forecast **\$868.5m** by 2030
- All high-grade gliomas eventually progress, no standard of care for recurrent disease
- New therapies with low toxicity urgently needed
- *In vitro* studies with patient-derived cell lines SFX-01 showed dose-dependent reduction in proliferation and migration.
- In orthotopic xenograft models, SFX-01 increased disease-free survival and lengthened tumour progression times, - synergistic with radiotherapy



Dr Claudio Festuccia - University of L'Aquila, Abruzzo


Colapietro *et al* 2021

*GlobalData

SFX-01 in Rhabdomyosarcoma cells and rhabdospheres

Published at ESMO sarcoma and rare diseases congress. Lugano 20-22 March 2023

- SFX-01 reduced rhabdomyosarcoma tumour cell growth
- SFX-01 produced a reduction in cell growth that was synergistic with radiation
- SFX-01 reduced tumour cell growth and rhabdosphere formation in radioresistant cells



RH30 radioresistant cells/rhabdospheres

Authors


S. camero¹, L. Milazzo², F. Vulcano², F. Pedini², P. Pontecorvi³, G. Gerini³, S. Ceccarelli³, E. Anastasiadou⁴, S. Pomella⁵, M. Cassandri⁵, A. Porrazzo⁵, R. Rota⁵, C. Marchese³, F. Midulla¹, F. Marampon⁶, F. Megiorni³

Author affiliations

- 1 Maternal, Infantile, And Urological Sciences, Sapienza University of Rome, 00161 - Rome/IT
- 2 Oncology And Molecular Medicine, Istituto Superiore di Sanità (ISS), 161 - Rome/IT
- 3 Experimental Medicine, Sapienza - Università di Roma, 00161 - Rome/IT
- 4 Clinical And Molecular Medicine, Sapienza - Università di Roma, 00161 - Rome/IT
- 5 Oncohematology, Ospedale Pediatrico Bambino Gesù, Rome/IT
- 6 Radiological Sciences, Oncology And Anatomical Pathology, Sapienza - Università di Roma, 00161 - Rome/IT

Half Year Highlights to 30 September 2023

Phase 1/1b Healthy Volunteer clinical study	To evaluate PK and PD effects of new SFX-01 formulation. PK Results delivered on schedule <i>PK Data QA review complete, tables and listings finalised</i>
Stalicia SA Collaboration <i>\$160.5m, double digit royalty</i>	Phase 1/1b study results shared with Stalicia Dose calculations for Autism Spectrum Disorder Phase 2 study underway
Manufacturing	Further enhancements on API production improve efficiency of manufacture
GBM clinical study	SFX-01 GBM study to be conducted as an ISS led by Prof Marjolein Geurts at the Erasmus University, Rotterdam. <i>Non-dilutive grant successful</i> <i>Ca £900k project value for pre-clinical/clinical studies</i>
Academic collaboration: SFX-01 radio-sensitisation	Evidence of enhancement of the effect of radiotherapy by SFX-01 <i>in vitro even in cells that had developed resistance to radiation</i> from Prof Marampon's Lab at La Sapienza University, Rome, <i>Further validated in mouse models in vivo, to be published</i>
Financials	Post-tax loss £1.5m (2022: loss £2.1m) Cash and short-term deposits at 30 September 2023 of £3.7m (30 September 2022: £7.2m) <i>Cash runway to Q4 2024 without further milestone payments</i>



Outlook

- Full data set from Phase 1b SFX-01 healthy volunteer study including gene expression data – RNA Seq
 - Evgen analysis
 - Stalicia analysis in autism – related genes
 - Start of Grant-funded GBM project in Erasmus MC Rotterdam, pre-clinical data 1/10/23
 - 2023 - 2024 pre-clinical data flow
 - Clinical study planning end 2024
 - Initial set of pre-clinical data from University of Michigan in colorectal cancer - 2024
 - Publication of rhabdomyosarcoma *in vitro* and *in vivo* work from Prof Marampon's group - 2024
 - Start of Autism Spectrum Disorder Phase 2 trial – 2024, further milestone payments from Stalicia totalling \$5.5m
- 



EVGEN
pharma


Conserve Cash

External
Validation of
Technology

Biotech
Imperatives
2023

Generate Pre-
clinical Data

Generate
Clinical
Data





EVGEN
pharma


Conserve Cash
**Runway to Q4
2024**

External
Validation of
Technology
**Stalicia,
Academic
Centres**

Biotech
Imperatives
2023

Generate Pre-
clinical Data
**La Sapienza,
Erasmus,
Michigan**

Generate
Clinical
Data
**Phase 1 PK/PD,
Erasmus GBM**





Evgen Pharma Plc
enquiries@evgen.com
www.evgen.com

AIM: EVG.L
NOMAD: Cavendish
IR: Instinctif, CAG